Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by talisman47on Nov 02, 2020 5:55pm

149 Views

Post# 31826925

RE:RE:RE:comments on Algernon progress....

It has now been a month , since October 2, when Algernon reported 75% enrollment. They were enrolling at a rate of over 3 new patients per day and now in 30 days they haven't signed up the remaining 37 to reach 150? I can't see that.... I still say they must have 150 before now and are probably the testing period would be over soon.

A news release of some kind can't be that far away.

I am a strong supporter and just impatient to hear the good news.

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features